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Supplemented very
low-protein diet in advanced
CRF: Is it money saving?
To the Editor: Based on data gained in a large co-
hort of patients on regular predialysis nephrologic care,
the proportion of subjects with hemoglobin (Hb) level
<11 g/dL, at a creatinine clearance level ≤20 mL/min/
1.73 m2, may be estimated at 60% [1]. Accordingly, two
thirds of predialysis patients should require erythropoi-
etin (EPO) treatment. The high cost of such therapy, how-
ever, remains a major limiting factor for its larger use.
We monitored EPO requirement in a group of patients
with advanced chronic renal failure (CRF) (creatinine
clearance ≤25 mL/min) across a two-year time period
[2]. At the start, patients were divided in a group treated
with very low-protein diet (VLPD, N = 10) (0.3 g/kg
body wt/day of protein of vegetable origin) supple-
mented by ketoanalogs and essential amino acids (Alfa
Kappa, Kedrion, Lucca, Italy administered at the dose
of 1 tablet/5 kg body wt/day) and another group on
usual low-protein diet (LPD, N = 10) (0.6 g of pro-
tein/kg body wt/day) groups did not differ in caloric in-
take (35 kcal/kg body wt/day), gender, age, body mass
index, renal disease, systolic and diastolic blood pres-
sure, and creatinine clearance. Hb levels were main-
tained within the target values in all patients during
the study period (VLPD, Hb = 11.5 ± 0.2 g/dL; LPD,
Hb = 11.5 ± 0.3 g/dL, P = NS). The main result of the
study was that the effective decrease of dietary protein
intake by 0.3 g/kg body wt/day allowed a reduction of
about 35% of the EPO dose required to maintain the tar-
get Hb level in advanced CRF. In addition, the decline of
renal function was reduced in VLPD (0.01 ± 0.22 mL/
min/month) with respect to LPD (−0.30 ± 0.16 mL/
min/month, P < 0.003). As a consequence, during the
24 months of follow-up, 2 VLPD patients and 7 LPD pa-
tients started chronic dialysis treatment.
We have now calculated the costs of therapy provided
in the two groups during the 2 years of observation
(Table 1). VLPD allowed a saving of economic resources
that can be quantified in almost €52,000 (cost in Euros)
for 10 patients during the study, which is a mean of
€2,600/pt/year for each patient with advanced CRF start-
ing a supplemented VLPD for the sole cost of therapy
during two years of treatment. These data remain to
be better defined in a larger population; however, it is
reasonable to suggest that prescription of supplemented
VLPD not only leads to amelioration of the main CRF-
related metabolic disturbances, but also allows a signifi-
cant saving of economic resources.
Table 1. Cost analysis of two years of treatment in CRF patients kept
at either very low-protein diet (VLPD) or low-protein diet (LPD)
VLPD LPD
(N = 10) (N = 10) Difference
Hypoproteic food 5110 4600 510
Alfa-kappa 54,987 0 54,987
Phospate binders 650 2184 −1534
Erythropoietin 68,081 109,196 −41,115
Iron 1642 791 851
Dialysis 16,527 81,972 65,445
Total 146,997 198,743 51,746
Data are in euros.
BIAGIO R. DI IORIO, VINCENZO BELLIZZI,
ROBERTO MINUTOLO, LUCA DE NICOLA,
CARMELA IODICE, and GIUSEPPE CONTE
Solofra and Naples, Italy
Correspondence to Dr. Biagio R. Di Iorio, U.O. di Nefrologia e Dialisi,
Ospedale “A. Landolfi,” Solfora (AV), C.da San Tommaso, 286, 83100
Avellino, Italy.
E-mail: br.diiorio@libero.it
REFERENCES
1. JUNGERS PY, ROBINO C, CHOUKROUN G, et al: Incidence of anemia and
use of epoetin therapy in pre-dialysis patients: A prospective study
in 403 patients. Nephrol Dial Transplant 17:1621–1627, 2002
2. DI IORIO BR, MINUTOLO R, DE NICOLA L, et al: Supplemented very
low-protein diet ameliorates responsiveness to erythropoietin in
chronic renal failure. Kidney Int 64:1822–1828, 2003
Patients developing anti-Epo
antibodies during rHuEpo
treatment do not express a
polymorphic variant of Epo
To the Editor: During the last few years, around 140
patients have developed pure red cell aplasia (PRCA)
during treatment with recombinant human erythropoi-
etin (rHuEpo). In most cases, PRCA was caused by the
production of neutralizing anti-EPO antibodies [1]. Al-
though antibody production was linked to the use of a
specific brand of rHuEpo, the reasons leading to antibody
production are not completely understood, and only a low
percentage of patients treated with this type of rHuEpo
develop antibodies, suggesting that they could have some
characteristics increasing their sensitivity to small modi-
fications of EPO. An attracting possibility would be that
these patients present a polymorphism in the coding re-
gion of the EPO gene. To test this hypothesis, we se-
quenced the coding region of the EPO gene in 9 patients
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that developed anti-EPO neutralizing antibodies ran-
domly chosen among 9 different French dialysis centers.
Genomic DNA was amplified by polymerase chain
reaction (PCR) and sequenced. The EPO gene con-
tains 5 exons, and only exons 2 to 5 code for EPO-
circulating protein. To sequence these exons, we ampli-
fied this region in two parts: 5′ part using the couple
of primers 5′-AGGCGCGGAGATGGGGGTG-3′; 5′-
TCAGGCTCGCAAATGAGA-3′ and 3′ part using the
couple of primers 5′-GCATACCTTCTGTTTGCTCAG-
3′; 5′-CTGGAGTGTCCATGGGACAG-3′. We did not
observe any difference with the published EPO se-
quences. Thus, although we cannot formally rule out that
translational modifications could lead to the production
of a modified circulating EPO molecule in these patients,
the high susceptibility of these patients to rHuEpo mod-
ifications is not caused by a polymorphism in the coding
region of their EPO gene.
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